In the TATTON trial, a promising ORR for EGFR‐TKI‐naïve with T790M mutant patients was found in the treatment of osimertinib and durvalumab, but this combination is unsafe due to a high incidence of grade 3/4 toxicity (39%), showing 22% interstitial lung disease (ILD).[199] In detail, two groups were set up: Group A patients received durvalumab monotherapy, while Group B was treated with the combination of osimertinib and durvalumab. Here, EGFR is linked to interstitial lung disease.